A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of GSK163090 in Subjects With Major Depressive Disorder.
Phase of Trial: Phase II
Latest Information Update: 21 Mar 2018
At a glance
- Drugs GSK 163090 (Primary)
- Indications Major depressive disorder
- Focus Adverse reactions; Therapeutic Use
- Sponsors GlaxoSmithKline
- 01 Apr 2011 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
- 01 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 May 2009 New trial record